Aims: FibroScan can predict liver fibrosis, which is closely correlated with the development of hepatocellular carcinoma. In many cases of liver tumour, we will make the wrong diagnosis in ultrasound. Our aim was to evaluate the correlation if FibroScan could be directed toward that tumour can be benign or else carcinoma in patients with viral hepatitis.
Methods: Cross description 88 patients HCC was determined from June 2006 to October 2008.
Group A was defined as patients who developed HCC with cirrhosis. Group B was defined as those with chronic hepatitis.
Analyse FibroScan value, characteristics of liver tumour in B-mode ultrasound, AFP.Using t-test to find differentiate about median FS among groups.
Results:
This study enrolled 88 patients with hepatitis B and C virus related chronic liver disease (72 males, 16 females, median age 50,6 years).
FibroScan: F4 (68 cases, mean FS: 47.3 KPa); F3 (14 cases, mean FS: 10.6 KPa); F2 (4 cases, mean FS: 7.6 KPa); F1 (2 cases; mean FS: 5.9 KPa).
We realize median FS differed significantly between group A with group B (α= 0.05).
Alternatively, median FS was not related with position of liver tumour (right lobe, left lobe or both); size of tumour (<2cm or >=2cm); form of lesion; AFP value (<100ng/ml or >=100ng/ml).
Conclusions: Our study suggest that liver stiffness measurement is a significant predictor of HCC development in patients with viral hepatitis. We offer all patients have liver tumours diagnosed on B-mode ultrasound to be performed FibroScan to evalue fibrosis stages.